SANOCHEMIA Pharmazeutika

What SANOCHEMIA Pharmazeutika does

SANOCHEMIA Pharmazeutika GmbH is an Austrian privately-held pharmaceutical company headquartered in Neufeld an der Leitha that develops, manufactures, and distributes diagnostic imaging pharmaceuticals. The company's core portfolio consists of contrast media for Computer Tomography (CT) and Magnetic Resonance Tomography (MRI), including products branded CT-Iopa-Body, MR-Gado-Body, MR-Liver-Body, and MR-Lymphnodes-Body, manufactured at a single Austrian site producing over 4 million units annually in vials ranging from 10 to 500 milliliters. Underlying technology combines established generic contrast media manufacturing with a differentiated pipeline of gadolinium-free MRI contrast agents based on superparamagnetic iron oxide nanoparticle (USPIO) technology, designed to serve patients with impaired kidney function and enable cell-specific imaging, with five new MRI products in registration or development stages.

Revenue is generated through three streams: (1) direct B2B sales of finished dosage forms (contrast media) to radiologists and healthcare institutions across over 50 countries; (2) supply of Active Pharmaceutical Ingredients (APIs) produced in-house under the 'made in Austria' positioning; and (3) Contract Development and Manufacturing Organization (CDMO) services offered to pharmaceutical partners seeking GMP-certified manufacturing capacity in Europe. The company also operates additional offices in Graz, Austria and Hong Kong to support international distribution. Ferumoxtran, the lead pipeline asset co-developed with strategic partner SPL, achieved both primary and secondary endpoints in the Phase III PROSTAPROGRESS study and had a Marketing Authorization Application submitted via EU decentralized procedure in February 2026 for detection and characterization of lymph node metastases in prostate cancer patients. Founded as a GmbH with 101-250 employees, Sanochemia operates as a privately-held entity with no public market listing or disclosed institutional investor base.

Name

SANOCHEMIA Pharmazeutika

Legal name

SANOCHEMIA Pharmazeutika GmbH

Website

https://sanochemia.at

Company type

Private

Operating status

Operating

Headcount range

101–250 employees

Short description

SANOCHEMIA Pharmazeutika GmbH is an Austrian pharmaceutical manufacturer that develops, produces, and distributes CT and MRI contrast media, APIs, and CDMO services to radiologists and healthcare institutions across 50+ countries.

Ownership category

akta.pro rank

Product category

Diagnostic Imaging Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Contract Development & Manufacturing for Generics (CDMO/CMO) (HLAIABAI)

akta.pro secondary industry

Nephrology & Urology Specialty Pharmaceuticals (HLAIACAH)

Keywords

• Diagnostic imaging pharmaceuticals
• MRI contrast media
• CT contrast agents
• Active pharmaceutical ingredients
• Contract pharmaceutical manufacturing

Headquarters

HQ city

Neufeld An Der Leitha

HQ country

Austria

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Personnel, Operations, Infrastructure

Revenue model

1. Finished Dosage Forms (Kontrastmittel): Development, production, and distribution of finished dosage forms (contrast agents) for MRI and CT imaging. Sanochemia manufactures over 4 million units annually in vials of 10–500 milliliters, with plans to add pre-filled syringes. Revenue is generated through direct B2B sales to radiologists and healthcare institutions across over 50 countries.
2. Active Pharmaceutical Ingredients (APIs): Development and production of high-quality Active Pharmaceutical Ingredients (APIs) as part of the company's 'made in Austria' offering. APIs complement the finished dosage form portfolio and are supplied to pharmaceutical partners and customers.
3. Contract Manufacturing Services (CDMO): Custom contract development and manufacturing services including tailored contract development and manufacturing, GMP services, and pharmaceutical manufacturing. These services are offered to partner companies seeking specialized manufacturing capabilities in Europe.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

SANOCHEMIA Pharmazeutika develops, manufactures, and distributes diagnostic imaging pharmaceuticals, primarily contrast media for Magnetic Resonance Tomography (MRI) and Computed Tomography (CT), alongside Active Pharmaceutical Ingredients (APIs) and finished dosage forms. The company also offers contract development and manufacturing (CDMO) services to pharmaceutical partners and operates an advanced R&D pipeline of gadolinium-free, USPIO-based MRI contrast agents targeting cell-specific imaging for patients with impaired kidney function.

Product overview

Sanochemia Pharmazeutika is a pharmaceutical company based in Austria that develops, produces, and distributes diagnostic imaging pharmaceuticals. The core product portfolio consists of contrast media for Computer Tomography (CT) and Magnetic Resonance Tomography (MRI), including CT-Iopa-Body, MR-Gado-Body, MR-Liver-Body, and MR-Lymphnodes-Body products. The company also produces Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms, manufacturing over 4 million units annually in vials of 10 to 500 milliliters. The pipeline includes Ferumoxtran, a USPIO-based MRI contrast agent for lymph node metastasis detection currently in registration. Contract manufacturing services (CDMO) are offered alongside R&D collaboration services. The strategic focus is on cell-specific MRI imaging with gadolinium-free agents based on superparamagnetic iron oxide nanoparticles, with over five new MRI products in development.

Differentiator

Problem solved

Functional benefit

Products and services

• CT Contrast Media (Iopa-Body) Sterile, high-viscosity injection solutions used in Computed Tomography (CT) imaging to improve the visibility of specific body structures and enhance diagnostic image quality. Designed for radiologists and healthcare institutions performing CT scans.
• MR Contrast Media - Gado (Gado-Body) Magnetic Resonance Tomography (MRI) contrast injection preparations that influence the magnetic effect to enable contrast-enhanced imaging of body structures. Designed for radiologists and healthcare institutions performing MRI procedures.
• MR Contrast Media - Liver (MR-Liver-Body) MRI contrast agent specifically designed for liver imaging applications, intended for radiologists and healthcare institutions performing liver MRI diagnostics.
• MR Contrast Media - Lymphnodes (MR-Lymphnodes-Body) MRI contrast agent designed for lymph node imaging applications, intended for radiologists and healthcare institutions performing lymph node MRI diagnostics.
• Ferumoxtran Ultra-small superparamagnetic iron oxide (USPIO) nanoparticle-based MRI contrast agent, currently in registration, intended for the detection and characterization of lymph node metastases in prostate cancer patients. Phase III PROSTAPROGRESS study achieved both primary and secondary endpoints, showing increased sensitivity and specificity for metastatic lymph node lesions exceeding current technologies.
• Active Pharmaceutical Ingredients (APIs) High-quality Active Pharmaceutical Ingredients synthesized at the Austrian manufacturing site, complementing the company's 'made in Austria' product offering. Supplied to pharmaceutical partners and customers as part of the API production business line.
• Finished Dosage Forms Finished pharmaceutical products developed, produced, and distributed by Sanochemia, including contrast media injection solutions in vials from 10 to 500 milliliters, with planned future expansion to ready-to-use pre-filled syringes.
• Contract Manufacturing Services (CDMO) Custom contract development and manufacturing services for pharmaceutical partners, including tailored contract development and production, extensive GMP services, and pharmaceutical and active ingredient manufacturing. Leverages Sanochemia's GMP-certified Austrian facility to serve partner companies seeking specialized manufacturing capabilities in Europe.

Quantifiable outcome

• Over 4 million contrast media units manufactured annually in vials from 10 to 500 milliliters
• +3 more outcomes

Named customers1 record

Segments1 record

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• SPL (Strategic Pharmaceutical Partner)coreStrategic or Co-development PartnerSanochemia collaborates with SPL (Sanochemia/SPL) on the development of MRI contrast agents, particularly the USPIO-based Ferumoxtran. The companies conducted the multi-center prospective PROSTAPROGRESS Phase III clinical study together, achieving both primary and secondary endpoints for the detection and characterization of lymph node metastases in prostate cancer patients. The partnership represents a co-development arrangement in advanced diagnostic imaging.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Bayer Radiology: Pharmaceutical conglomerate's radiology division selling MRI contrast agents (e.g., gadobutrol) globally. Comparable through overlapping contrast media offering, but operating as part of a much larger diversified pharma portfolio.
• GE HealthCare: Global medical imaging and diagnostics incumbent with a significant contrast media business alongside imaging hardware and software. Overlaps with Sanochemia in MRI/CT contrast but competes across a vastly broader portfolio.
• Thermo Fisher Scientific (Patheon CDMO): Global pharmaceutical services giant operating CDMO capabilities including sterile injectables and API manufacturing through its Patheon business. Comparable as a CDMO peer, though vastly larger and more diversified than Sanochemia's contract offering.

Direct peers

• Recipharm: European pharmaceutical CDMO offering sterile fill-finish, APIs, and finished dosage forms across multiple therapeutic areas. Directly comparable to Sanochemia's contract manufacturing business and Austrian/German-speaking footprint.
• Aenova Group: German-headquartered pharmaceutical CDMO with sterile injectables, solid dosage, and API capabilities. Comparable through similar European GMP manufacturing footprint and customer overlap in pharmaceutical contract manufacturing.
• Bracco Imaging: Italian family-owned contrast media and imaging agent company serving radiology worldwide. Closest direct peer given similar focus on MRI/CT contrast products and comparable European manufacturing heritage.
• Guerbet: French-headquartered specialist in diagnostic imaging contrast media and related solutions. Direct competitor to Sanochemia's MRI/CT contrast agent portfolio, with deeper product breadth and global sales coverage.
• Lantheus Holdings: US-based specialty radiopharmaceutical and imaging agent company focused on diagnostics including MRI ultrasound contrast. Comparable as a focused imaging-diagnostics specialist pursuing differentiated agents versus commodity generics.

Emerging players

• Fareva: European pharmaceutical contract manufacturer with sterile injectable capabilities among other formats. Comparable through CDMO service offering to pharmaceutical partners, though broader in scope than Sanochemia's imaging-focused operation.
• Curium Pharma: Global nuclear medicine and PET imaging agent specialist. Adjacent peer sharing the radiologist customer base and imaging-agent development model, though focused on radiopharmaceuticals rather than MRI/CT contrast.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/sanochemia
• Facebookfacebook.com/Sanochemia-Pharmazeutika-100071046136529

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SANOCHEMIA Pharmazeutika